SonoSite goes nano

Article

SonoSite goes nanoOther headlinesMerge Healthcare expects mixed 2Q

SonoSite goes nano
SonoSite is out with a new handcarried ultrasound system, one that is lighter and stronger than other such systems in the company’s product line. Underlying the paradox of the six-pound  NanoMaxx is the magnesium shell that replaces the plastic casing of other handcarried products in the SonoSite portfolio. NanoMaxx is pending FDA clearance, but is available for sale outside the U.S.,The Bothell, WA, company is aiming the new product, like others in its portfolio, at point-of-care applications in physicians’ offices and at the hospital bedside. It comes equipped with five transducers to support general exams from cardiac to small parts and interventions, including thoracic assessment and needle aspirations. It can be wall mounted, placed on an exam table, or operated from a compact, maneuverable stand.


Merge Healthcare expects mixed 2Q
Preliminary results for the second quarter show that Merge Healthcare will meet expectations for revenue in the second quarter, thanks in large part to $2.2 million in nonrecurring  revenue. Merge will not be able to do as much for the 2Q bottom line, however, which will sag in the quarter from a $3.6 million write down on the sale of an equity stake in the radiology company Eklin Medical Systems. Merge will get $1.4 million from the sale with most of the money being collected in the third quarter of 2009. With the various calculations all told, Merge expects net income for 2Q09 of between $100,000 and $800,000, a substantially worse showing than the $2.8 million of the previous quarter but much better than the of $18.3 million net loss in the year earlier quarter. Merge provided the unaudited results “to provide timely, material information to Merge’s shareholders, the market and the shareholders of etrials Worldwide, who are currently considering Merge’s pending tender offer for all of the shares of etrials,” according to the company.
 

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.